LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
9.15
-0.14 (-1.51%)
Apr 29, 2026, 9:40 AM EDT - Market open
LENZ Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 25.18 | 20.16 | 35.14 | 44.44 | 18.31 |
| Short-Term Investments | 267.17 | 188.87 | 30.65 | - | - |
| Cash & Short-Term Investments | 292.35 | 209.03 | 65.79 | 44.44 | 18.31 |
| Cash Growth | 39.86% | 217.70% | 48.05% | 142.75% | - |
| Accounts Receivable | 0.33 | - | - | - | - |
| Other Receivables | 2.1 | 1.1 | - | - | - |
| Receivables | 2.43 | 1.1 | - | - | - |
| Inventory | 2.94 | - | - | - | - |
| Prepaid Expenses | 3.7 | 1.67 | 1.45 | 2.2 | 0.02 |
| Restricted Cash | - | 0.11 | - | - | - |
| Total Current Assets | 301.41 | 211.92 | 67.24 | 46.64 | 18.32 |
| Property, Plant & Equipment | 1.92 | 1.99 | 0.37 | 0.28 | 0.01 |
| Long-Term Deferred Charges | - | - | 2.74 | - | - |
| Other Long-Term Assets | 2.54 | 1.4 | 0.02 | 0.03 | 0 |
| Total Assets | 305.88 | 215.3 | 70.38 | 46.95 | 18.34 |
| Accounts Payable | 4.17 | 4.26 | 5.71 | 4.76 | 0.46 |
| Accrued Expenses | 16.56 | 5.58 | 12.67 | 4.29 | 0.79 |
| Current Portion of Leases | 0.47 | 0.57 | 0.14 | 0.1 | - |
| Current Income Taxes Payable | - | - | - | 0.35 | - |
| Total Current Liabilities | 21.19 | 10.41 | 18.51 | 9.5 | 1.25 |
| Long-Term Leases | 0.35 | 0.81 | 0.19 | 0.15 | - |
| Other Long-Term Liabilities | - | - | 0.12 | 0.07 | - |
| Total Liabilities | 21.54 | 11.22 | 18.83 | 9.71 | 1.25 |
| Common Stock | 0 | 0 | 5.91 | 5.91 | 5.9 |
| Additional Paid-In Capital | 511.24 | 348.9 | 2.52 | 1.1 | 0.25 |
| Retained Earnings | -227.14 | -145.01 | -95.25 | -25.28 | -14.47 |
| Comprehensive Income & Other | 0.24 | 0.2 | 0.01 | - | - |
| Total Common Equity | 284.34 | 204.08 | -86.81 | -18.27 | -8.31 |
| Shareholders' Equity | 284.34 | 204.08 | 51.55 | 37.24 | 17.08 |
| Total Liabilities & Equity | 305.88 | 215.3 | 70.38 | 46.95 | 18.34 |
| Total Debt | 0.82 | 1.38 | 0.33 | 0.25 | - |
| Net Cash (Debt) | 291.53 | 207.65 | 65.47 | 44.19 | 18.31 |
| Net Cash Growth | 40.40% | 217.19% | 48.14% | 141.39% | - |
| Net Cash Per Share | 10.12 | 9.76 | 33.42 | 4.67 | 1.96 |
| Filing Date Shares Outstanding | 31.35 | 27.54 | 25.53 | 9.63 | 9.36 |
| Total Common Shares Outstanding | 31.34 | 27.52 | 9.74 | 9.63 | 9.36 |
| Working Capital | 280.23 | 201.51 | 48.73 | 37.14 | 17.07 |
| Book Value Per Share | 9.07 | 7.42 | -8.91 | -1.90 | -0.89 |
| Tangible Book Value | 284.34 | 204.08 | -86.81 | -18.27 | -8.31 |
| Tangible Book Value Per Share | 9.07 | 7.42 | -8.91 | -1.90 | -0.89 |
| Machinery | 0.66 | 0.48 | 0.07 | 0.05 | 0.02 |
| Leasehold Improvements | 0.11 | 0.1 | 0.01 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.